Generalizability of trial results to elderly Medicare patients with advanced solid tumors (alliance 70802)

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Lamont, Elizabeth B ^a,b   Schilsky, Richard L ^c   He, Yulei ^b   Muss, Hyman ^d   Cohen, Harvey Jay ^e   Hurria, Arti ^f   Meilleur, Ashley ^b   Kindler, Hedy L ^g   Venook, Alan ^h   Lilenbaum, Rogerio ⁱ   Niell, Harvey ^j   Goldberg, Richard M ^k   Joffe, Steven ^l  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ YALE CANCER CENTER   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DECISION MAKING; FEMALE; GERIATRIC PATIENT; HISTOLOGY; HUMAN; LUNG CANCER; MALE; MEDICAL DECISION MAKING; MEDICARE; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; SOLID TUMOR; SURVIVAL TIME; AGE; CANCER REGISTRY; EDUCATIONAL STATUS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; UNITED STATES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; EDUCATIONAL STATUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SEER PROGRAM; UNITED STATES;

EID: 84930452357     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju336     Document Type: Article

References (41)

1. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897.
2. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
4. IOM (Institute of Medicine). 2013. Delivering high-quality cancer care: Charting a new course for a system in crisis. Washington, DC: The National Academies Press.
5. National Cancer Institute. SEER: Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/. Accessed May 10, 2007.
6. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds). SEER Summary Staging Manual - 2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
7. Lamont EB, Lan L. Sensitivity of Medicare claims data for measuring use of standard multi-agent chemotherapy regimens. Medical Care. 2014;52(3):e15-e20.
8. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-3622.
9. Niell HB, Herndon II JE, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752-3759.
10. Lilenbaum RC, Herndon II JE, List MA, Desch C, Watson DM. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005;23(1):190-196.
11. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320(7233):469-472.
12. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Int Med. 2001;134(12):1096-1105.
13. Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB. Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy. Cancer. 2013;119(3):691-699.
14. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. New Engl J Med. 2012;367(17):1616-1625.
15. Mack JW, Cook EF, Wolfe J, Grier HE, Clearly PD, Weeks JC. Understanding of prognosis among parents of children with cancer: parental optimism and the parent-physician interaction. J Clin Oncol. 2007;25(11):1357-1362.
16. Mackillop WJ, Stewart WE, Ginsburg AD, et al. Cancer patients' perceptions of their disease and its treatment. Br J Cancer. 1998;50:355-359.
17. IOM (Institute of Medicine). 2013. Delivering high-quality cancer care: Charting a new course for a system in crisis. http://www.iom.edu/~/media/Files/Report%20Files/2013/Quality-Cancer-Care/qualitycancercare-rb.pdf. Published September 10th, 2013. Accessed September 8, 2014.
18. Mavroudis D, Papadakis E, Veslemes M, et al. Greek Lung cancer Cooperative Group. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatinetoposide as first-line treatment in patients with smallcell lung cancer. Ann Oncol. 2001;12:463-470.
19. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
20. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999:91(1):66-72.
21. Period Life Table, 2010. Social Security Administration Website. Available at: http://www.ssa.gov/oact/STATS/table4c6.html. Accessed June 23, 2014.
22. National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Available at: http://www.cdc.gov/nchs/data/hus/hus10.pdf. Published February 2011. Accessed July 7, 2014.
23. Ervin RB. Prevalence of functional limitations among adults 60 years of age and over: United States, 1999-2002. Advance data from vital and health statistics; no 375. Hyattsville, MD: National Center for Health Statistics. 2006.
24. Søgaard MI, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3-29.
25. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106(11):2452-2458.
26. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
27. Gross CP, Filardo G, Mayne ST, Krumholz HM. The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer. 2005;103(3):483-491.
28. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357.
29. Murphy MM, Simons JP, Ng SC, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(11):2968-2977.
30. Hardy D, Liu CC, Xia R, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer. 2009;115(10):2199-2211.
31. Baldwin L, Dobie SA, Billingsley K, et al. Explaining Black-White Differences in Receipt of Recommended Colon Cancer Treatment. J Natl Cancer Inst. 2005;97(16):1211-1220.
32. Lamont EB, Zaslavsky AM, Subramanian SV, Meilleur A, He Y, Landrum MB. Elderly breast and colorectal cancer patients' clinical course: patient and contextual influences. Med Care. 2014;52(9):809-817.
33. Simpson DR, Martinez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013;105(23):1814-1820.
34. Du XLI, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic disparities in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(4):660-669.
35. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph nodepositive, operable breast cancer. Cancer. 2009;115(13):2999-3008.
36. Hsieh MC, Chiu YW, Velasco C, Wu XC, O'Flarity MB, Chen VW. Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer. J Registry Manag. 2013;40(4):180-187.
37. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004;363:263-270.
38. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term) ? Evidence for a "trial effect" J Clin Epidemiol. 2001;54:217-224.
39. Vist G, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome. BMJ. 2005;330(7501):1175.
40. Walters LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001:285(21):2750-2756.
41. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824-1831.